California shows Trump a thing or two about cutting drug costs

12 July 2018
drug_money_big

When it comes to reducing the cost of prescription medicines, where US President Donald Trump has increasingly failed, a new price transparency law in California appears to be succeeding.

The new law, called SB-17, requires drugmakers to give government, insurers and other payers advance notice of increases over a certain amount.

Apparently as a result of the law coming into effect, Switzerland’s Novartis (NOVN: VX) and Roche (ROG: SIX), as well as Gilead Sciences (Nasdaq: GILD) and Novo Nordisk (NOV: N), have either cancelled or reduced planned price increases for over 10 different products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical